Table 5.

Subgroup analysis of patients with and without cirrhosis. Cases and controls compared with respect to occurrence of screening with either USS or AFP at given time intervals prior to the index date.

Cirrhosis
	Controls N = 62	Cases N = 62	Unadjusted OR (95% CI)	Adjusted ORa (95% CI)
0–4 years prior to index date
Either USS or AFP	46 (74.2%)	25 (40.3%)	0.16 (0.06–0.46)	0.17 (0.03–0.91)
0–3 years prior to index date
Either USS or AFP	45 (72.6%)	24 (38.7%)	0.19 (0.07–0.50)	0.24 (0.06–1.00)
0–2 years prior to index date
Either USS or AFP	41 (66.1%)	22 (35.5%)	0.24 (0.10–0.59)	10.30 (0.08–1.15)
0–1 year prior to index date
Either USS or AFP	31 (50.0%)	22 (35.5%)	0.53 (0.24–1.13)	0.76 (0.24–2.39)
No cirrhosis
	Controls N = 107	Cases N = 107	Unadjusted OR (95% CI)	Adjusted OR* (95% CI)
0–4 years prior to index date
Either USS or AFP	53 (49.5)	32 (29.9)	0.22 (0.09–0.54)	0.07 (0.02–0.29)
0–3 years prior to index date
Either USS or AFP	48 (44.9)	28 (26.2)	0.29 (0.13–0.63)	0.12 (0.04–0.38)
0–2 years prior to index date
Either USS or AFP	42 (39.3)	24 (22.4)	0.28 (0.12–0.65)	0.12 (0.04–0.41)
0–1 year prior to index date
Either USS or AFP	35 (32.7)	18 (16.8)	0.32 (0.14–0.71)	0.16 (0.06–0.46)

^aAdjusted for age, race/ethnicity, BMI, diabetes, alcohol use disorder, HIV coinfection, HBV e Ag positive, HBV DNA maximum viral load, years from HBV diagnosis to index date, and receipt of CT or MRI in the window.

Abbreviations: OR – odds ratio, CI – confidence interval, USS – ultrasound, AFP – alpha fetoprotein